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The current opioid crisis in the United States has been escalating for the past two decades, and it has
only worsened since the emergence of coronavirus disease in 2019 (COVID-19) (1, 2). The COVID19 pandemic brought up unprecedented challenges in dealing with the opioid crisis, including
those falling under the (i) public policy level: disruptions in addiction treatment recovery services,
delivery of mental health/harm reduction services; (ii) individual level: loss of work and worsening
of pre-existing psychiatric conditions; and (iii) interpersonal level: a lack of peer support, all of
which may lead to increased opioid use, relapse risk, and overdoses (1, 3). The opioid epidemic
and overdose deaths have been described as a “triple wave epidemic,” with the first wave involving
prescription opioids, followed by heroin-related overdoses, and the current wave involving illicit
fentanyl and fentanyl analogs (4). The triple wave crisis has been amplified by a “fourth wave,”
which has been dominated by fentanyl but also includes cocaine and methamphetamine-related
deaths (5). Although there has been a decline in overdose deaths involving prescription opioids,
the opioid crisis has worsened overall (5). The growing use of synthetic opioids [such as illicitlymanufactured fentanyl (IMF)] in combination with cocaine and methamphetamine has resulted in
significant increases in co-use-related overdose deaths (5).
The driving factors for stimulant use in recent years include the increasing availability of
methamphetamine in the markets with the relative absence of certain opioids making the former
more attractive pills (6). To some extent, restricting access to prescription opioids may be linked
to an increase in methamphetamine use (6). One of the possible explanations for the rise in
methamphetamine usage, according to user experience, is that it served as an opioid substitute,
offered a synergistic high, and balanced out the effects of opioids in order to regain “normalcy” (6).
Although the link between opioid and stimulant concurrent use (e.g., speed-ball or goof-ball) is
not novel, attention has been drawn due to an increase in the number of stimulant-related overdose
deaths, most likely due to fentanyl being increasingly mixed into cocaine and methamphetamine.
Concurrent use of stimulants and opioids is becoming more common, and polydrug use (e.g., couse of a stimulant along with an opioid) has been linked to drug overdose deaths (6). Sedatives,
particularly benzodiazepines or alcohol, are known to interact with opioids and are frequently
implicated in opioid overdose deaths due to their respiratory depressant effect. The combination
of heroin, cocaine, and injected speedballs is also a known predictor of overdose (7). Although
the pharmacodynamics of stimulants in combination with opioids are not fully understood, one
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poly drug use (i.e., a mixture of methamphetamine and cocaine
with fentanyl), and counterfeit prescription pills.
Aside from synthetic opioids and stimulants, there has been
a dramatic increase in the number of prescription and overthe-counter (OTC) drugs owing to their abuse potential at
high doses or idiosyncratic methods of self-administration (14).
Schifano et al. investigated the rising popularity and availability
of prescription drugs (pregabalin, bupropion, venlafaxine,
olanzapine, clenbuterol, and loperamide) (15). In line with this,
pregabalin and gabapentin abuse appears to have increased
dramatically in recent years among people with SUD, particularly
those abusing opioids. Gabapentin was the tenth most commonly
prescribed medication in the United States in 2016, while
pregabalin ranked eighth in invoice drug spending with $4.4
billion in sales. According to the Canadian study, concomitant
gabapentin and opioid exposure was associated with a 49%
increased risk of dying from an opioid overdose (16), and due to
such alarming rates, gabapentin is now considered an emerging
threat in today’s opioid epidemic. Identifying some potential
gaps and challenges related to the emerging crisis of novel
psychoactive substances, Schifano et al. identify the potential
factors influencing this rapidly shifting drug scenario (15). For
example, web-based pro-drug information to vulnerable subjects
such as children and adolescents and psychiatric patients, failure
to identify abuse or misuse potential during pre-marketing
processes, and a lack of post-marketing substance abuse
surveillance. Pharmacovigilance measures should be considered
in cases of prescription and OTC drug abuse in order to detect,
assess, understand, and prevent adverse effects or other drugrelated problems.

possible explanation for speedball-related mortality is that
cocaine causes severe vasoconstriction, causing the body to use
more oxygen, whereas heroin’s depressant effects slow breathing
rates, leading to respiratory failure. It’s unclear if the link between
these drugs and overdose mortality is due to drug interactions
or if drug users overdose on heroin to reduce their stimulated
“highs” (7). Our personal experience at a methadone clinic
in rural Vermont, as well as current literature suggests that
individuals who use concurrent opioids and stimulants believe
stimulants are safer, combining stimulants and opioids to offset
the negative effects of opioids, such as withdrawal symptoms,
limiting opioid use, finding cheaper substitutes for heroin,
relieving fatigue, lethargy, and some combining to enhance a
“high” (6, 8). However, in many cases, fentanyl is mixed with
cocaine or methamphetamine without the user’s knowledge,
and a person with no tolerance to opioids may suffer a fatal
overdose (9, 10). The United States reported the greatest ever
overdose fatalities ever recorded—totaling 93,000 deaths due to
OUD (11) (Ellis et al.). Along with research efforts, recently
published literature reports also underline polydrug use, which
is more prevalent among individuals with OUD (Ellis et al.).
As a result, the federal and state level agencies have made an
effort to promote preclinical and clinical research on the effects
of co-use of stimulants and opioids, as well as the development
and implementation of evidence-based interventions to prevent
drug overdose.

SHIFTING TRENDS OF DRUG USE AND
PREVALENCE
According to the CDC, during 2015–2018, an estimated
1.6 million US adults, on average, reported past-year
methamphetamine
use;
52.9%
of
persons
using
methamphetamine in the past year met diagnostic criteria
for methamphetamine use disorder, and nearly 25% reported
injecting methamphetamine within the past year (12).
The National Survey on Drug Use and Health (NSDUH)
estimated that in 2019, 2 million individuals aged 12 or older
used methamphetamine, up from 1.4 million in 2016 (13).
Acknowledging the dearth of data on co-use, and to improve
our understanding of polysubstance use among individuals with
OUD, a retrospective analysis conducted from 1991 to 2020
was assessed (Ellis et al.); the authors found an 82.4% exposure
to stimulants among people with OUD, whereas crack/cocaine
(68.6%), prescription stimulants (50.6%), and methamphetamine
(63.1%) were commonly reported. Among 7,109 individuals, the
mean age of first exposure to either substance was 22.3 years.
Using a national opioid surveillance system and analyzing data
from 124 OUD treatment centers between 2017 and 2020, Ellis
et al. report that that the average age for “initial exposure” to
any stimulant or opioid has increased from 10 years to 23.5
years since the 1990s. These large shifts in populations may be
linked to healthcare practitioners and systems’ efforts to raise
public awareness about the consequences of the medications
(Ellis et al.). Therapeutic and preventive efforts should consider
the newest wave’s key demographics (i.e., shifting ages, rurality),
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OPIOIDS AND STIMULANTS TRENDS IN
GENERAL AND DURING COVID-19
Experiments involving human and animal subjects provide some
evidence that stimulants such as amphetamine potentiate the
analgesic effects of morphine (17). Psychostimulant drugs in
animal studies present with intrinsic analgesic properties and
also enhance the analgesic properties of opioids, which may
explain the user groups’ reasoning. Deaths involving cocaine
and psychostimulants have increased in recent years, particularly
among opioid users. In 2017, opioids were involved in nearly
three-fourths of cocaine-related deaths and nearly half of
psychostimulant-related deaths (18). Ellis et al. reported an
increase in past-month methamphetamine use among opioiddependent individuals, from 18.8% in 2011 to 34.2% (6). A recent
study analyzing data from the 2015–2019 National Surveys on
Drug Use and Health (NSDUH) reported that among those
reporting past month heroin usage, methamphetamine use
increased nearly 5-fold (from 9 to 44%). Similarly, those who
used heroin in the past year used methamphetamine twice as
much (22.5 to 46.7%). Rurality, past year injection drug use, and
serious mental illness have all been linked to methamphetamine
use among individuals who use heroin (19). The use of
stimulants alone or in combination with other drugs has been
linked to several social, mental, and physical health problems
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disorders, more specifically craving changes in daily habits, which
only showed modest change during the COVID-19 pandemic
(22). The Italian cohort posits that craving for drugs is considered
as a significant therapeutic target for lowering the risk of relapse
and improving patients’ quality of life (22). Low levels of craving
during a pandemic like COVID-19 may be attributable to a
perceived lack of availability of the drugs and reduced societal
pressure on people using drugs. The study found that craving
was lower in inpatients than in outpatients, highlighting the
importance of residential treatment in substance use disorders
(22). The findings of this study could be put into practice as one
of many options for dealing with the 4th wave crisis.

such as homelessness, drug-related crime, overdoses, suicide,
cardiovascular diseases, and infectious disease transmission (e.g.,
Hepatitis C and HIV) (20).
The global prevalence of stimulants has drastically risen
since 2010. Over 5 million Americans reported current cocaine
use in 2020, while over 2.5 million Americans aged 12 and
older reported using methamphetamine in the previous year.
According to recent estimates, there are ∼18 million cocaine
users worldwide, with the highest rates in the US (2.1%). A
recent study identified that areas dense in black and Hispanic
racial/ethnic groups had a 575% increase in cocaine and opioid
mortality rate compared to a 184% increase across white groups
(8). From 2015 until 2019, psychostimulants’ overdose among US
adults, largely methamphetamine, increased by 180% (from 5526
to 15,489 overdosage estimates) (20). A rise in psychostimulantrelated mortality could be attributed to increased availability
and market expansion in areas and user groups traditionally
associated with methamphetamine use (10). According to reports
by US federal agencies, methamphetamine availability in the
United States continues to be widespread, its purity and potency
remain high, and its price remains relatively low (10). In our
observation working with patients, patients report an increase in
stimulant use due to the growing fear of fentanyl adulteration of
heroin and the risk of overdose.
The COVID-19 pandemic has had an impact on the network
of cocaine trafficking supply lines, but it has not significantly
reduced overall supply to the United States. Despite the rising
crisis, there are no FDA-approved pharmacological treatments
to treat amphetamine or cocaine addiction, and unfortunately
no antidotes to treat stimulant overdoses. During the COVID19 era, the US, saw a rise in overdose deaths caused by illicit
fentanyl, fentanyl analogs, methamphetamine, and cocaine, often
in combination or mixed with other drugs, evidenced by the
alarming 100,306 drug overdose deaths in the US, during
the 12 months ending in April 2021, a 28.5% increase from
the 78,056 deaths during the same period the year before
(21). The main drivers were synthetic opioids (i.e., fentanyl),
but stimulants like cocaine and methamphetamine were also
increased. During the pandemic, drug use increased in both
quantity and frequency, leading to an increase in drug overdose
deaths. A plausible explanation for the increase in substance
use during the pandemic included coping with emotional stress,
social isolation, economic stress related to COVID-19, and
increased general anxiety and depression. The rising number of
overdose deaths involving synthetic opioids could be attributed
to heroin shortages and the economic downturn during the
pandemic, which led to users switching to substances such as
low-cost fentanyl and its derivatives.
The disruption in heroin supply has also exacerbated harmful
drug use, such as the use of home-produced injectable opioids
like “krokodil,” also known as “Russian Magic,” a cheap but
extremely dangerous substitute for heroin. During the peak of
the pandemic, we saw two cases at our clinic who reported
using krokodil in the absence of heroin. Contrary to the majority
of reports indicating a significant increase in drug use and
overdose deaths around the world, an Italian study assessed
the psychopathological burden in people with substance use
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RECOMMENDATIONS AND FUTURE
DIRECTIONS
In light of the many risks and consequences of stimulant
and opioid use, some interventions can reduce the rate of
fatal opioid overdoses. For example, (i) the scalability of rapid
fentanyl test strips to detect fentanyl in illicit drugs may be
useful in harm reduction interventions (23). (ii) Initiating or
continuing medications for opioid use disorder. (iii) Due to
the rise in polydrug overdoses, treatment providers must assess
for concurrent substance use disorders and offer evidencebased treatments. (iv) Distribution of naloxone through costeffective, pharmacy- and community-based programs; expanding
the locations of naloxone distribution centers, particularly in
minority populations, rural communities, and homeless shelters.
(v) Naloxone is not effective against stimulant overdose, but
it should be offered due to the rise of concurrent opioid use.
(vi) Educating individuals not to use drugs alone, ensuring that
naloxone is available and that people who use drugs and their
loved ones know how to use it. (vii) Educating individuals
that they may require repeated doses of naloxone to reverse
an overdose due to the potency of IMF and fentanyl analogs
(24). (viii) On a personal level, individuals exposed to opioids
and stimulants together ought to be aware of symptoms, pulse
rate, heart rate, and rhythm for prevention (25). (ix) Although
there are no FDA-approved medications to treat stimulant use
disorders, treatment providers offer evidence-based treatment
approaches such as community reinforcement, motivational
interviewing, and cognitive-behavioral therapy combined with
contingency management (12). (x) identifying jurisdictions and
vulnerable groups (e.g., IV drug users) who are at higher risk of
infectious disease, and expanding harm reduction approaches for
those groups, e.g., syringe exchange programs (SEPs). (xi) With
the growing COVID-19 and opioid epidemic, wearable monitors
with inbuilt artificial intelligence-powered sensors linked to
medical devices can become key in attaining urgent medical
attention (26). This growing problem of stimulant-opioid co-use
requires an emphasis on access to evidence-based treatment.
This paper serves as a call to action for the high prevalence
of substance and opioid co-use, albeit with a paucity of data
(Ware et al.). Polydrug use develops due to various reasons
such as accessibility, motivation, and awareness. The fourth
wave of the opioid crisis has been on the rise since the
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late 20th century, however, with the COVID-19 pandemic in
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